Matt Hoffman

Observations from more than 1000 cases of stroke suggest that enhanced paramedic assessment should not be used to increase thrombolysis volume but may influence the quality of treatment decisions.

The FDA has accepted an sBLA for a version of Genentech's ocrelizumab with a shorter administration time for the treatment of relapsing and primary progressive MS.

Retrospectively analysis data suggest that while the majority of epileptics have no significant worsening in bone mineral density, they maintain an amplified risk of suffering major osteoporotic fractures.

Data out to 11 years suggest that individualized doses of brivaracetam (Briviact; UCB Pharma) are safe and effective in reducing focal and primary generalized seizures.

"Mind Moments," a podcast from NeurologyLive, brings you an exclusive interview with Fernando Pagan, MD.

In those with secondary progressive MS, evaluating diffusely abnormal white matter may provide a useful measure for therapies aiming to protect at-risk tissue, which may be able to slow progression.

The CEO of Biohaven Pharmaceuticals discussed the company’s new collaboration, which has made rimegepant (Nurtec ODT) available for prescription through Cove’s telemedicine platform.

The director of the Multiple Sclerosis Program at Cleveland Clinic Lou Ruvo Center for Brain Health discussed the correlation between age and disease duration in MS, as well as what was learned from a subanalysis of the EXPAND study of siponimod.

Biohaven Pharmaceutical’s oral acute migraine agent rimegepant (Nurtec ODT) is the first branded medication available through Cove’s platform, which provides consults with independent health care providers and access to prescriptions.

The assistant professor of Neurology, Concussion and Headache Medicine divisions, Mayo Clinic, Scottsdale, Arizona discussed the evolving migraine treatment landscape and how they have been incorporated into her practice.

The director of the MS Comprehensive Care Center at Stony Brook University discussed the need for more innovative approaches to DMTs and better communication about disease processes from physicians.

Significant advancements in genetics and the implementation of artificial intelligence have begun to carve a new, more personalized path for the diagnosis and treatment of seizure disorders.

The director of epilepsy research and epilepsy clinical trials at NYU Langone Health’s Comprehensive Epilepsy Center spoke about the recent study findings from a trial of Staccato alprazolam.

Despite solanezumab (Eli Lilly) and gantenerumab (Roche and Genentech) failing to meet the DIAN-TU trial primary end point in inherited Alzheimer disease, the international undertaking provided some positive takeaways for the clinical community.

A multicenter, cross-sectional, observational, Spanish nationwide study’s findings suggest that those with Parkinson disease dementia may be predisposed to impulse control disorder symptoms and related behaviors.

Prospective, observational study data suggest that MRS fat fractions and MRI quantitative T2 values can provide disease progression measures in a sensitive and noninvasive manner.

The PROMISE-2 clinical trial data suggest that the recently approved, IV-administered eptinezumab (Vyepti; Lundbeck) is effective in both 100- and 300-mg doses for patients with chronic migraine.

Pediatric patients with focal-onset seizures experienced significant reductions in their 24-hour seizure rates compared to placebo when administered adjunctive 14 mg/kg per day pregabalin (Lyrica; Pfizer).

The executive vice president of research and development at Jazz Pharmaceuticals discussed what the clinical community needs to know ahead of the regulatory decision on JZP-258 in the treatment of cataplexy and excessive daytime sleepiness in narcolepsy.

New data suggest that brain changes in the posterior cingulate cortex and precuneus as a result of SDB may increase the risk of Alzheimer disease, supporting prior findings which imply a link between the conditions.

Study data suggest that even in early disease, motor complications are common and accompanied by a greater burden of nonmotor symptoms than previously known.

ImStem Biotechnology plans to initiate a phase 1 study of the human embryonic-mesenchymal stem cell agent sometime in 2020. Preclinical data suggest its potential to reduce MS relapses and disability progression, and encourage disease arrest.

The president and CEO of Engage Therapeutics, along with the company’s executive VP and COO, discussed its investigational Staccato alprazolam product in the abortive treatment of seizures.

Real-world, observational cohort data suggest that Biogen’s nusinersen (Spinraza) is safe and effective in the treatment of spinal muscular atrophy.

Preliminary data from the ASPIRO study of Audentes Therapeutics resamirigene bilparvovec gene therapy suggests it is safe with improvements in neuromuscular and respiratory function.

Pear Therapeutics’ Somryst intervention provides tailored neurobehavioral interventions intended to improve the symptoms of insomnia, via cognitive behavioral therapy and algorithm-driven sleep restriction.

The novel oxybate agent is seeking an indication for the treatment of cataplexy and excessive daytime sleepiness in those 7 years and older with narcolepsy. The PDUFA date is July 21, 2020.

Catabasis’s small molecule NF-kB inhibitor showed promise in phase 2, and the phase 3 PolarisDMD study (NCT03703882) of edasalonexant is fully enrolled and expected to read out in late 2020.

Axsome Therapeutics has accelerated the completion of its phase 2/3 trial of AXS-05 in patients with Alzheimer disease agitation, with top-line results now expected to read out in Q2 2020, a full quarter ahead of the prior scheduled time.

Data from the DELOS and SYROS studies of idebenone suggest that investigational DMD treatment has a treatment effect maintained for up to 6 years, which can reduce hospitalizations, bronchopulmonary adverse events, and systemic antibiotic use.